GB971307A — 5-anilinopyrimidines
Assigned to Wellcome Foundation Ltd · Expires 1964-09-30 · 62y expired
What this patent protects
The invention comprises compounds of general formula <FORM:0971307/C1/1> in which each of R and R1 is hydrogen or lower (1-4C) alkyl, each of Y and Z is amino, chlorine, hydroxy or mercapto, and the aryl group may bear substituents and has 6-13 carbon atoms; and their prepa…
USPTO Abstract
The invention comprises compounds of general formula <FORM:0971307/C1/1> in which each of R and R1 is hydrogen or lower (1-4C) alkyl, each of Y and Z is amino, chlorine, hydroxy or mercapto, and the aryl group may bear substituents and has 6-13 carbon atoms; and their preparation by reacting a compound of formula <FORM:0971307/C1/2> where X is bromine or chlorine, and Y1 is amino, hydroxy or mercapto with an aniline or N-alkylaniline in a glycol solvent between 180 DEG C. and 220 DEG C., and if desired subjecting the primary product to chlorination, amination and thiation. Pharmaceutical compositions comprising compounds I and excipients are mentioned (tablets, capsules, cachets, powders, granules, suppositories, ampoules, solutions, suspensions, ointments). The compounds have antibacterial and antimetabolic activities and have use as antimalarials and immune-response suppressants.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.